Marshall Wace
VINC

Marshall Wace’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Marshall Wace’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,678
Closed -$255K – 3103
2024
Q3 		$255K Buy
17,678
+1,251
+8% +$17.2K ﹤0.01% 2210
2024
Q2 		$266K Buy
16,427
+12,849
+359% +$322K ﹤0.01% 2207
2024
Q1 		$362K Buy
+3,578
New +$226K ﹤0.01% 2049
2021
Q4 		– Sell
-1,122
Closed -$363K – 4363
2021
Q3 		$363K Sell
1,122
-1,296
-54% -$378K ﹤0.01% 2559
2021
Q2 		$628K Buy
+2,418
New +$737K ﹤0.01% 2031

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's VINC Position: Q4 2024 in Review

Marshall Wace sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2024, closing a stake of 17,678 shares — an estimated $255K sold.

Marshall Wace first reported a position in VINC in Q2 2021 and held it in 5 quarters. The position peaked at $628K in Q2 2021. 22 funds tracked by Wall St. Rank hold VINC as of Q4 2024.

  • Marshall Wace reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Marshall Wace sold 17,678 Vincerx Pharma, Inc. Common Stock shares in Q4 2024, an estimated $255K.
  • Marshall Wace first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • Marshall Wace's Vincerx Pharma, Inc. Common Stock position peaked at $628K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2024.

Based on Marshall Wace's 13F filing for Q4 2024, filed 13 Feb 2025.